



**FOR IMMEDIATE RELEASE**

**Case Study Illustrates Cell Specific Productivities of up to 80 pcd  
Utilizing Bioinformatics and Selexis' Patented Technology, MARtech™**

*Selexis SA to Present Case Study at the Antibody Development and Production Conference*

Geneva, Switzerland – February 24, 2006 – Selexis SA, a Swiss-based biotechnology company specializing in high yield and stable cell line development for therapeutic protein manufacturing announced today that it will present the case study “Construction of Stable Mammalian CHO Cell Lines Producing High Yield Recombinant Antibodies by Combining Bioinformatics and High Throughput Transfection Process” at the next Antibody and Development & Protein Conference in Carlsbad, California (March 1-3, 2006).

Dr. Pierre-Alain, Ph.D., Head of Research and Development at Selexis, will present the case study on Wednesday, March 1, 2006 at 10:15 AM as part of the “Design of Expression Systems” track. Selected slides from the lecture, including data on MARtech™, will also be available following the meeting.

**Presentation Abstract**

***Construction of Stable Mammalian CHO Cell Lines Producing High Yield Recombinant Antibodies by Combining Bioinformatics and High Throughput Transfection Process***

We have developed a novel technology to rapidly create high-antibody (MAb)producing cell lines. The technology involves inserting a MAR genomic elements into the heavy and light chain expression vectors. Iterative transfections allow the targeting of the vectors into unique chromosome's loci. Using CHO-DG44 cells, clones have been selected that show cell specific productivities of up to 80 pcd.

- more -

SELEXIS EUROPE  
18 chemin des Aulx  
1228 Plan-les-Ouates  
Switzerland

T +41 (0)22 308 93 60  
F +41 (0)22 308 93 61

SELEXIS USA  
655, Montgomery St. STE 540  
San Francisco, CA 94111  
USA

T +1 415 273 51 41  
F +1 415 837 32 04

## About Selexis

Selexis is a privately held biotechnology company dedicated to the development of expert services and technologies for comprehensive and rapid solutions for stable, high yield cell line development and protein manufacturing for therapeutic drugs. The Company's unique seven step, high through put process, which includes the forth generation patented MARtech™, reduces traditional cell line development (DHFR) from 12 months to 3 months (after transfection to isolating cell clones) without any change in the scale-up process. For more information please visit <http://www.selexis.com>

## About IBC Life Sciences, "Antibody Development and Production" Conference

Accelerate your antibody therapeutic program by attending the highest quality conference on antibody development and production in the industry. This event delivers the most recent advances in upstream processing, as well as the latest strategies and technologies to optimize downstream processing. With inside information from leading industry experts that will help you save time, reduce costs and increase production, this event is considered a "must attend" by scientists and executives from entry level to CEO. For more information, please visit <http://www.ibclifesciences.com/antibodyprod>.

*This news release contains forward-looking statements that involve a number of known and unknown risks and uncertainties. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. These statements are only predictions and actual events or results in future periods may differ materially from what is currently anticipated. In particular, we cannot assure you that we will be able to successfully develop or commercialize products based on our technology, particularly in light of the significant uncertainty inherent in developing drug delivery products, conducting clinical trials and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our joint ventures or our collaborations with other companies in the U.S. and abroad will successfully develop products or become profitable, that our business strategy will be successful or that we will be able to carry out our plans for 2007.*

MARtech™ is a trademark of Selexis, SA.

### **MEDIA CONTACT:**

Robert Meister  
602-953-1716  
[robert.meister@selexis.com](mailto:robert.meister@selexis.com)

### **MORE INFORMATION:**

EUROPE  
Igor Fisch, Ph.D.  
41 (0)22 308 93 60  
[igor.fisch@selexis.com](mailto:igor.fisch@selexis.com)

UNITED STATES  
Cori Gorman, Ph.D., M.B.A.,  
415-273-5141  
[cori.gorman@selexis.com](mailto:cori.gorman@selexis.com)